Clinical Trial

Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab

Study acronym: BRAND
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, open-label, single-arm phase II clinical trial investigating the efficacy and safety of niraparib monotherapy maintenance in HRD-positive newly diagnosed advanced epithelial ovarian cancer (EOC), including primary peritoneal and/or fallopian tube tumors, following response to front-line chemotherapy in combination with bevacizumab. A total of 116 patients will be enrolled.
Trial Details
NCT Number NCT06141265
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Enrollment 116 participants
Start Date 2023-11-01
Primary Completion 2026-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2023-11-21